CD274 and neoplasm: Hyperprogressive disease—an increased tumour growth rate during treatment—is a new pattern of progression that was recently reported for patients treated with PD‐1‐/PD‐L1‐targeted immunotherapy.23, 37, 38 Four (8%) patients in our cohort had hyperprogression during immunotherapy.